NOX Stock Overview
A biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Noxopharm Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.10 |
| 52 Week High | AU$0.17 |
| 52 Week Low | AU$0.044 |
| Beta | 0.78 |
| 11 Month Change | 10.53% |
| 3 Month Change | 59.09% |
| 1 Year Change | 84.21% |
| 33 Year Change | -80.37% |
| 5 Year Change | -72.37% |
| Change since IPO | -43.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| NOX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | 1.7% |
| 1Y | 84.2% | 18.7% | 17.2% |
Return vs Industry: NOX exceeded the Australian Biotechs industry which returned 18.7% over the past year.
Return vs Market: NOX exceeded the Australian Market which returned 17.2% over the past year.
Price Volatility
| NOX volatility | |
|---|---|
| NOX Average Weekly Movement | 13.4% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: NOX's share price has been volatile over the past 3 months.
Volatility Over Time: NOX's weekly volatility has decreased from 20% to 14% over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Gisela Mautner | www.noxopharm.com |
Noxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia. It primarily develops Veyonda, a formulation of idronoxil for the treatment of solid tumors. The company also develops LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types.
Noxopharm Limited Fundamentals Summary
| NOX fundamental statistics | |
|---|---|
| Market cap | AU$30.68m |
| Earnings (TTM) | -AU$3.58m |
| Revenue (TTM) | AU$2.40m |
14.6x
P/S Ratio-9.8x
P/E RatioIs NOX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOX income statement (TTM) | |
|---|---|
| Revenue | AU$2.40m |
| Cost of Revenue | AU$2.94m |
| Gross Profit | -AU$534.81k |
| Other Expenses | AU$3.04m |
| Earnings | -AU$3.58m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.012 |
| Gross Margin | -22.28% |
| Net Profit Margin | -149.07% |
| Debt/Equity Ratio | 0% |
How did NOX perform over the long term?
See historical performance and comparison